From Discovery to Development: The Role of RUO Antibodies in Biologics Process Development

 Why RUO Antibodies Matter in Process Development

Process development is the bridge between early discovery and clinical manufacturing. At this critical stage, teams must characterize molecules, monitor quality, and establish reproducible assays that will scale into regulated environments. Reliable antibodies are central to this work.

ProSci’s Research Use Only (RUO) antibodies, available through both our extensive catalog and custom antibody development services, empower process development teams with precision tools to evaluate biologics. With more than 27 years of expertise, we provide antibodies designed to meet the unique demands of critical quality attributes (CQAs), CMC batch release, PK assays, potency testing, and advanced biologics analytics.

RUO Antibodies Across Process Development Workflows

Critical Quality Attributes (CQA) & CMC Batch Release

Challenge: Ensuring lot-to-lot consistency and regulatory readiness.

Solution: RUO antibodies detect product- and process-related impurities including host cell proteins (HCPs), glycosylation variants, and aggregation markers.

Impact: Supports comparability studies and reliable CMC batch release decisions.

 

Pharmacokinetics (PK) & ADA Monitoring

Anti-idiotype antibodies provide precise measurement of therapeutic drug levels.

Distinguish therapeutic antibodies from endogenous immunoglobulins.

Enable development of bridging PK assays and monitoring of anti-drug antibodies (ADA) to inform dose optimization and safety.

 

Potency Assays

Potency is central to regulatory acceptance of biologics.

RUO antibodies support both cell-based and biochemical assays to demonstrate functional activity.

• Fc effector function antibodies (e.g., ADCC, CDC reporters) enable evaluation of immune mechanisms of action.

https://www.prosci-inc.com/blog/from-discovery-to-development-the-role-of-ruo-antibodies-in-biologics-process-development/